KALA BIO (KALA)

• Market cap: $185M
• 1 day: 4.08%
• 5 days: -16.08%
• 1 month: -21.1%
• 3 months: -66.99%
• 6 months: -84.82%
• Year to date: -67.98%
• 1 year: -94.25%
• 5 years: -99.94%
• 10 years: -99.98%
• Sector: Healthcare
• Industry: Biotechnology

About: Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.

Employees: 38